August 2013 Incyte Corp. has announced two new trials that are currently recruiting ET and PV patients: Recruiting Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea in Polycythemia Vera (PV) and Essential Thrombocythemia (ET) Recruiting Switch Study From Hydroxyurea to Ruxolitinib for RELIEF of Polycythemia Vera Symptoms: The Relief Study According to representatives from Incyte,… Read More »NEW TRIAL RECRUITING PV AND ET PATIENTS
In 2010, The U.S. House of representatives declared September to be a time in which to raise awareness and support activities that will help people living with all types of blood cancer. In September the MPN community will have a unique opportunity to draw attention to polycythemia vera, essential thrombocythemia and myelofibrosis by celebrating national Blood… Read More »Take action this September to change your prognosis
September 3, 2013 by Andrew Schafer, MD, Scientific Advisory Board Chair and Chairman of Medicine, Weil Cornell Since 2000, the MPN Research Foundation has provided nearly $9 million in research funding to advance the treatment of the myeloproliferative neoplasms (essential thrombocythemia, polycythemia vera and myelofibrosis.) It is a modest amount relative to the magnitude of… Read More »MPN BCAM 2013: PATIENTS IN ACTION
October 26, 2013 On Thursday October 24, 2013, the MPNRF met with Representatives and Senators from around the country to deliver a message: stop sequestration now and restore funding to cancer research. While organizations like MPNRF work hard to fund research independent of the government, the funds raised from individual donors can only go so… Read More »MPNRF GOES TO WASHINGTON
Don’t save the date. Instead, join us from the comfort of your own home on #GivingTuesday, December 3rd, 2013. We’re celebrating Giving Tuesday this year by giving you the night off. We are NOT holding a gala on December 3rd to help raise money for MPN research. Instead, you’re invited to stay in and support PV, ET, and… Read More »GIVING TUESDAY
By Sam Klepper As a board member of the MPN Research Foundation for more than 10 years, it has been encouraging to see the progression of the scientific community’s understanding of the MPNs and the development of an initial set of targeted therapies. One of the challenges we face as a foundation is determining which… Read More »CALR MUTATION: FOCUS AREA ONE
January 29, 2015 The New England Journal of Medicine has just published a paper co-authored by Claire N. Harrison, D.M., Ruben Mesa, M.D. and Srdan Verstovsek, M.D., Ph.D. among others, describing the outcome of a trial measuring Ruxolitinb in polycythemia vera patients who are intolerant or who do not respond to Hydroxyurea. Patients were randomly… Read More »NEJM REPORTS ON RANDOMIZED TRIAL OF RUXOLITINIB VS PHLEBOTOMY IN HYDROXYUREA-RESISTANT PV
January 29, 2015 The MPD Research Consortium has just issued its most recent newsletter. This edition features updates on their clinical trials including several which are recruiting patients right now. Download the January edition now.
This research study is by QuintilesIMS (sponsored by Incyte Corporation)Background QuintilesIMS Global Services, a worldwide consulting firm, is conducting a research study to better understand the experience of ET patients. QuintilesIMS plans to interview patients who have been diagnosed with ET oneâ€onâ€one over the phone. QuintilesIMS is looking for interested people to share what they have… Read More »SHARE YOUR EXPERIENCE WITH ESSENTIAL THROMBOCYTHEMIA (ET) TO HELP SHAPE THE FUTURE OF TREATMENT
